Trump Unveils Regeneron Deal to Lower Drug Prices
Summary
President Trump announced a deal with Regeneron to lower drug prices, part of his most-favored-nation initiative, which includes offering a new hearing-loss therapy for free. Regeneron is the latest major drugmaker to make pricing concessions under agreements with the Trump administration.
How coverage differs
Left outlets reported Trump's Regeneron deal as part of a broader initiative, while right outlets enthusiastically framed it as a significant achievement and a win for consumers.
- Left: Trump's drug price deal: a last-minute election push Left-leaning outlets reported President Trump's deal with Regeneron to lower drug prices, noting it is part of his 'most-favored-nation' initiative. They highlight the administration's efforts to secure pricing concessions from major drugmakers, including a new hearing-loss therapy offered for free.
- Right: Administration secures lower drug prices for American patients Right-leaning outlets enthusiastically reported President Trump's successful deal with Regeneron to lower drug prices, framing it as a significant achievement for his administration. They highlighted the 'most-favored-nation' initiative as a win for American consumers, securing concessions from major drugmakers.